Laurence Nieto

Laurence Nieto

Auto-generated profile, based on publicly available information

Laurence Nieto

Laboratoire de Pharmacologie et de Biologie Structurale, CNRS UPR 9062, 205, route de Narbonne, 31077 Toulouse Cedex, France

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2016 in Cancer Research
Verified
Journal Article
Closed access
PDF file
ILIkrame Lazar
Ikrame Lazar
ECEmily Clement
Emily Clement
SDStéphanie Dauvillier
Stéphanie Dauvillier
DMDelphine Milhas
Delphine Milhas
MDManuelle Ducoux-Petit
Manuelle Ducoux-Petit
LNLaurence Nieto
Laurence Nieto
Malignant progression results from a dynamic cross-talk between stromal and cancer cells. Recent evidence suggests that this cross-talk is mediated to a significant extent by exosomes, nanovesicles secreted by most cell types and which allow the transfer of proteins, lipids, and nucleic acids between cells. Adipocytes are a major component of several tumor microenvironments, including that of invasive melanoma, where cells have migrated to the adipocyte-rich hypodermic layer of the skin. We show that adipocytes secrete exosomes in abundance, which are then taken up by tumor cells, leading to increased migration and invasion. Using mass spectrometry, we analyzed the proteome of adipocyte exosomes. Interestingly, these vesicles carry proteins implicated in fatty acid oxidation (FAO), a feature highly specific to adipocyte exosomes. We further show that, in the presence of adipocyte exosomes, FAO is increased in melanoma cells. Inhibition of this metabolic pathway completely abrogates the exosome-mediated increase in migration. Moreover, in obese mice and humans, both the number of exosomes secreted by adipocytes as well as their effect on FAO-dependent cell migration are amplified. These observations might in part explain why obese melanoma patients have a poorer prognosis than their nonobese counterparts. Cancer Res; 76(14); 4051–7. ©2016 AACR.

10 January 2020 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
ECEmily Clement
Emily Clement
ILIkrame Lazar
Ikrame Lazar
CACamille Attané
Camille Attané
LCLorry Carrié
Lorry Carrié
SDStéphanie Dauvillier
Stéphanie Dauvillier
LNLaurence Nieto
Laurence Nieto
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

7 May 2015 in Pigment Cell & Melanoma Research
Verified
Journal Article
Closed access
PDF file
ILIkrame Lazar
Ikrame Lazar
ECEmily Clement
Emily Clement
MDManuelle Ducoux‐Petit
Manuelle Ducoux‐Petit
LDLaurence Denat
Laurence Denat
VSVanessa Soldan
Vanessa Soldan
LNLaurence Nieto
Laurence Nieto

17 January 2019 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
CLCamille Lehuédé
Camille Lehuédé
XLXia Li
Xia Li
SDStéphanie Dauvillier
Stéphanie Dauvillier
CVCharlotte Vaysse
Charlotte Vaysse
CFCamille Franchet
Camille Franchet
CMCatherine Muller
Catherine Muller
Clinical studies suggest that obesity, in addition to promoting breast cancer aggressiveness, is associated with a decrease in chemotherapy efficacy, although the mechanisms involved remain elusive. As chemotherapy is one of the main treatments for aggressive or metastatic breast cancer, we investigated whether adipocytes can mediate resistance to doxorubicin (DOX), one of the main drugs used to treat breast cancer, and the mechanisms associated. We used a coculture system to grow breast cancer cells with in vitro differentiated adipocytes as well as primary mammary adipocytes isolated from lean and obese patients. Drug cellular accumulation, distribution, and efflux were studied by immunofluorescence, flow cytometry, and analysis of extracellular vesicles. Results were validated by immunohistochemistry in a series of lean and obese patients with cancer. Adipocytes differentiated in vitro promote DOX resistance (with cross-resistance to paclitaxel and 5-fluorouracil) in a large panel of human and murine breast cancer cell lines independently of their subtype. Subcellular distribution of DOX was altered in cocultivated cells with decreased nuclear accumulation of the drug associated with a localized accumulation in cytoplasmic vesicles, which then are expelled into the extracellular medium. The transport-associated major vault protein (MVP), whose expression was upregulated by adipocytes, mediated both processes. Coculture with human mammary adipocytes also induced chemoresistance in breast cancer cells (as well as the related MVP-induced DOX efflux) and their effect was amplified by obesity. Finally, in a series of human breast tumors, we observed a gradient of MVP expression, which was higher at the invasive front, where tumor cells are at close proximity to adipocytes, than in the tumor center, highlighting the clinical relevance of our results. High expression of MVP in these tumor cells is of particular interest since they are more likely to disseminate to give rise to chemoresistant metastases. Collectively, our study shows that adipocytes induce an MVP-related multidrug-resistant phenotype in breast cancer cells, which could contribute to obesity-related chemoresistance.

27 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
LPLaurence Pellerin
Laurence Pellerin
LCLorry Carrié
Lorry Carrié
CDCarine Dufau
Carine Dufau
LNLaurence Nieto
Laurence Nieto
BSBruno Ségui
Bruno Ségui
NANathalie Andrieu-Abadie
Nathalie Andrieu-Abadie
Metabolic reprogramming contributes to the pathogenesis and heterogeneity of melanoma. It is driven both by oncogenic events and the constraints imposed by a nutrient- and oxygen-scarce microenvironment. Among the most prominent metabolic reprogramming features is an increased rate of lipid synthesis. Lipids serve as a source of energy and form the structural foundation of all membranes, but have also emerged as mediators that not only impact classical oncogenic signaling pathways, but also contribute to melanoma progression. Various alterations in fatty acid metabolism have been reported and can contribute to melanoma cell aggressiveness. Elevated expression of the key lipogenic fatty acid synthase is associated with tumor cell invasion and poor prognosis. Fatty acid uptake from the surrounding microenvironment, fatty acid β-oxidation and storage also appear to play an essential role in tumor cell migration. The aim of this review is (i) to focus on the major alterations affecting lipid storage organelles and lipid metabolism. A particular attention has been paid to glycerophospholipids, sphingolipids, sterols and eicosanoids, (ii) to discuss how these metabolic dysregulations contribute to the phenotype plasticity of melanoma cells and/or melanoma aggressiveness, and (iii) to highlight therapeutic approaches targeting lipid metabolism that could be applicable for melanoma treatment.

20 April 2017 in Pigment Cell & Melanoma Research
Verified
Journal Article
Closed access
PDF file
ECEmily Clement
Emily Clement
ILIkrame Lazar
Ikrame Lazar
CMCatherine Muller
Catherine Muller
LNLaurence Nieto
Laurence Nieto